Liangjiang New Area will aim to further develop pharmaceutical and medical device industry clusters and to build China's major production base of generic drugs whose patent has expired or is about to expire.
It will speed up projects related to digestion, metabolism, cardiovascular system and other fields with great potential in the near future as well as antineoplastic drugs, immunomodulators and other areas with great potential in the long term. It will consolidate chemical API advantages, promote R&D and industrialization of innovative chemical drugs, further R&D of generic drugs and scale up production levels.
It will build western China's largest medical device industry base, and strengthen the dominance of conventional medical equipment and disposable, aseptic medical devices - while focusing on promoting high-end medical equipment, home medical equipment, digital medical product development and manufacturing.
It will also accelerate biopharmaceuticals research and development, and bring in incubators that help convert patents into a productive force to co-construct a technology platform for chemical synthesis, cell culture, extraction and purification, drug screening, safety evaluation, scale-up experiments and so on. During the 12th Five-year Plan period, the overall investment in the industry has reached 20 billion yuan, and the pharmaceutical and medical device industry cluster has achieved an output value of 30 billion yuan, accounting for 1/3 of the city's total.
Chongqing lies at the convergence of the Yangtze and Jialing rivers.